India-based Biocon announced the publication of two peer-reviewed studies from the phase 3 INSIGHT program evaluating MYL-1701P, its aflibercept biosimilar approved by the FDA as Yesafili (aflibercept-jbvf), for the treatment of diabetic macular edema.1,2 The first study, published June 29, 2026, reported findings from a 20-week, multicenter, open-label extension study of participants with diabetic macular edema who completed the 52-week global phase 3 INSIGHT trial. The extension evaluated safety, efficacy, and immunogenicity in patients who either continued treatment with MYL-1701P or switched from reference aflibercept to MYL-1701P.1 According to Biocon, safety, efficacy, and immunogenicity profiles were comparable between the continuation and switch groups. Best corrected visual acuity, central subfield thickness, and ETDRS letter gains were maintained through the extension period in both treatment groups.
Filter by:
Retina Today
Alexis Warren, MD
Jonathan Lin, MD, PhD
The sale price gets all the attention. How much wealth you keep depends on something else entirely: whether the experts around you are working from the same playbook.
David Mandell, JD, MBA
Thoughtful planning is essential.
Alan Winig
These financial, operational, and strategic considerations can help you make the right decision between renting and owning.
Jefferey T. Brockette, MSHA
Alan Ruby, MD
How operational safety nets can turn practice data into early warnings for workflow and reimbursement issues.
Bill James, MHA, COE
This article reviews common reasons why retina imaging claims may be denied or audited and documentation best practices to help reduce these risks.
Matthew Baugh, MHA, COT, OCS, OCSR
Consider a surgical approach that can better accommodate a thin sclera in patients with this connective tissue disorder.
Hind Safi, MD; Younes Tlemçani, MD, PhD; Sarah Belghmaidi, MD, PhD; and Abdeljalil Moutaouakil, MD, PhD
Experts came together to discuss peer review, ROP care, uveitis management, and dry AMD therapies.
Alexander Shaer, BS, and Trisha Ortiz, BS
An amniotic membrane transplant was used to treat a patient with chronic, complex macular hole.
Osama M. Ahmed, MD, and Mohsin H. Ali, MD
A multimodal approach to treatment led to meaningful visual improvement despite poor prognostic signs on OCT.
Mena Kozman, MD; Aaron Shi, MD; Nyaari Kothiya; Sami Dahr, MD; and Rabia Karani, MD, MPH
Be aware of this potential complication after functional endoscopic sinus surgery.
Amol Ganvir, MBBS, DO, DNB (Ophth), and Chekitaan Singh, MBBS, DNB, FMRF
As part of our 20th anniversary, Retina Today is digging into the archives to reflect on how much the profession has changed.
Rohit Varma, MD, MPH
Persistent CME may be caused by inflammatory and ischemic mechanisms, even after apparent viral quiescence.
Collin Richards, MD, and David Fell, MD
Allen C. Ho, MD; Robert L. Avery, MD; and Lejla Vajzovic, MD, FASRS
Quantitative biomarkers may add a new dimension to the assessment and risk stratification of diabetic retinopathy.
Kallista Zhuang, BA; Shinji Kakihara, MD, PhD; and Amani A. Fawzi, MD
Diabetic tractional retinal detachments are challenging for even the most seasoned surgeons. Following these steps can help minimize complications.
Neil Sheth, MD, MBA, and Dimitra Skondra, MD, PhD
A look at the hope and hurdles of global screening implementation.
Majda Hadziahmetovic, MD; Michael D. Abramoff, MD, PhD; Abdullah AlQahtani, MD, DES, DISSO, FEBO; Gavin Tan Siew Wei, MBBS, PhD; Sobha Sivaprasad, MBBS, MS, DM, FRCS, FRCOphth; Lloyd Harrison-Williams, MD; and Jorge C. P. Rocha, MD, PhD
Kevin J. Corcoran, COE, CPC, CPMA, FNAO
Eyetube
View More
New Retina Radio is a place to hear stories about retina that are told nowhere else.
The RETINAWS panel led by Kourous Rezaei, MD, discuss techniques for vitreoretinal surgery and rare surgical cases.
Eyewire headlines are now available as a weekly podcast! Listen Now
